AI New King "Not as Good as a Native Dog": Million Trades Volume Transforms Anthropic Trillion-Dollar Market Mirage
BlockBeats News, May 7th – AI giant OpenAI is about to go public with Anthropic, and the current public market valuations of the two giants are approximately $850 billion and $380 billion, respectively. In comparison, the implied valuations in the on-chain Pre-IPO market are even more exaggerated. Currently, Anthropic's implied valuation on Jupiter has skyrocketed to over $1.2 trillion, while on Hyperliquid, it is $1.143 trillion. OpenAI's implied valuation on Jupiter is $1.05 trillion.
Behind the optimistic implied valuations of AI giants in the on-chain market is actually a house of cards. Currently, Anthropic's daily trading volume on Jupiter is only $1.39 million, with only 329 traders in the past 24 hours, and a total of 3,530 holding addresses, which is less than a moderately popular meme token. Today's 329 traders have driven Anthropic's valuation to surpass $1.2 trillion and overtake OpenAI as the leading AI company. The $1.2 trillion market cap is so exaggerated that if Anthropic successfully IPOs, it will directly become the 11th largest publicly traded company globally, creating a new myth in business history. In addition, Anthropic's daily trading volume on Hyperliquid is also in the million-dollar range, with an open interest of only $6.7 million.
If the on-chain market is a house of cards, then what about the traditional market? Similarly, there is a bubble cycle among AI giants. Massive cloud service providers such as Microsoft, Nvidia, Google, and Amazon have heavily invested in large model companies like OpenAI and Anthropic, investing billions of dollars, and these AI companies in turn use almost all the funds to purchase investors' products—Nvidia's GPUs, Microsoft/Amazon/Oracle's cloud computing power, etc. On the surface, revenue is surging, valuations are soaring, and all parties are "making money," but it's actually the same money circulating within a closed circle, creating a false prosperity, relying on continuous new capital injections and high cash burn, while real profits and widespread productivity gains have yet to be realized.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
siRNA rising star ADARx (ADRX.US) launches $350 millions IPO, AbbVie subscribes to 4.9% of shares with a maximum investment of $100 millions
ADARx plans to raise $350 millions and list on Nasdaq. AbbVie will invest up to $100 millions to acquire a 4.9% stake, with a median valuation of $1.8 billions.
Roche (RHHBY.US) weight loss injection shows positive mid-term trial results: average weight loss of 15.5% over 48 weeks, blood sugar levels drop by 2.65%.
The experimental weight-loss injection enicepatide simultaneously lowered blood sugar and body weight in overweight or obese patients with type 2 diabetes during a mid-stage clinical trial.
SPAC company Silicon Valley Acquisition II (SVATU.US) applies for US stock IPO, aiming to raise up to 220 millions USD.
The blank-check company (SPAC) Silicon Valley Acquisition II submitted a filing to the U.S. Securities and Exchange Commission (SEC) on Monday, planning to raise up to 220 millions USD through an initial public offering (IPO).
China’s gold imports exceeded 1,000 tons by August, surpassing the total for all of 2025.

